NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison

Profitability

This table compares NKGen Biotech and CEL-SCI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
CEL-SCI	N/A	-238.05%	-104.65%

Valuation and Earnings

This table compares NKGen Biotech and CEL-SCI”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94 million	($2.45)	-0.12
CEL-SCI	N/A	N/A	-$26.92 million	($12.61)	-0.29

CEL-SCI is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 12.1% of CEL-SCI shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 9.9% of CEL-SCI shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

NKGen Biotech has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, CEL-SCI has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Summary

NKGen Biotech beats CEL-SCI on 6 of the 8 factors compared between the two stocks.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.